You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The loop-mediated isothermal amplification test runs on a battery-powered device to provide self-testing individuals with results in approximately 30 minutes.
The company will use a portion of the proceeds to enter into capped call transactions and the remainder for various corporate activities.
The Sydney, Australia-based firm has licensed a single biomarker which it plans to develop into a test for triaging COVID-19 patients.
A new GeoMx Digital Spatial Profiler assay will have up to 30 protein targets and will be validated for potential use as a laboratory-developed test.
The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.
HeartGenetics offers a range of genetic tests and services including ones for general wellness, cardiovascular conditions, and pharmacogenetics.
The company said that it has received CE marks for two additional SARS-CoV-2 tests, including one that detects the virus and influenza A/B.
The firm's new application of its BCR-ABL test will be able to detect p190 transcripts and is currently for research use only.
The group is developing an ultrasensitive nanoparticle-enhanced plasmonic biosensor to detect RAS single nucleotide variants in plasma.
Qiagen received CE IVD marking for its NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test and for a saliva collection kit for its single-plex NeuMoDx SARS-CoV-2 assay.
The Regeneron Genetics Center will provide whole-exome sequencing for 150,000 patients who will be able to opt-in to receive actionable results.
The partners aim to refine a saliva-based SARS-CoV-2 test developed by Yale that received Emergency Use Authorization from the FDA earlier this year.
The company also announced John Leite, the former leader of clinical business development activities at Illumina, had joined the firm as chief business officer.
A deal with Burning Rock will allow the test to be used in trials and clinics in China, and Myriad will license its technology to French and German pathology labs.
In a study involving 1,300 blood samples from pregnant women, Myriad researchers demonstrated that their method could increase the fetal fraction for almost all.
The agency approved Agilent/Dako's PD-L1 IHC test for identifying TNBC patients who are most likely to respond to Keytruda and chemo.
Novitas added multiple leukemia biomarkers to its coverage determination, as well as the ThyGeNEXT molecular panel.
The company highlighted efforts to expand the use of its tests in the analysis of cerebrospinal fluid, an area in which research collaborations have begun to yield some data.
Life science product revenues nearly doubled, offsetting a continuing slide in the firm's diagnostics revenues.
The drug discovery and preclinical oncology services provider attributed the revenue decline to the impact of the SARS-CoV-2 pandemic on its customers.
Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.
Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.
The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.
In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.